Targeting hypoxic response for cancer therapy.

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment Research

Background:

• Hypoxic tumor microenvironment (HTM) promotes aggressive tumor behaviors, including metabolic reprogramming, oncogene activation, epithelial-mesenchymal transition, and resistance to therapies.
• Cancer cells adapt to HTM by enhancing glycolysis, glucose transport, acidosis regulation, and angiogenesis, largely orchestrated by HIF1A.
• Mitochondrial functions are significantly altered in hypoxic tumors, characterized by the Warburg and reverse Warburg effects.

Purpose of the Study:

• To provide a comprehensive overview of the characteristics of the hypoxic tumor microenvironment.
• To highlight novel therapeutic strategies targeting cancer cell adaptive responses to hypoxia.
• To focus on therapies currently under clinical investigation for HTM-related challenges.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of molecular mechanisms underlying cancer cell adaptation to hypoxia.
• Synthesis of information on therapeutic strategies targeting HIF1A and metabolic pathways.

Main Results:

• HTM is a key driver of tumor aggressiveness and therapeutic resistance.
• HIF1A activation is a critical mediator of cancer cell adaptation to hypoxia and a marker of poor prognosis.
• Cancer cells exhibit significant metabolic plasticity, including Warburg and reverse Warburg effects, to survive in HTM.

Conclusions:

• Understanding HTM characteristics is crucial for developing effective cancer treatments.
• Targeting cancer cell adaptation to hypoxia, particularly HIF1A activation and metabolic reprogramming, offers promising therapeutic avenues.
• Novel therapeutic strategies currently in clinical trials show potential for overcoming HTM-induced resistance.